Cullinan Therapeutics Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Very happy to have Cullinan Therapeutics with us for the next fireside chat, CEO Nadim Ahmed and Jeff Jones, CMO. Nadeem, do you want to kick it off with a brief overview of Cullinan, and then we will get into the Q&A?
Sure, yeah. Happy to do that. I think the first thing I would say is we are very pleased to have a portfolio of leading T-cell engagers across oncology and immunology, and they are both, all three are clinical stage. At the same time, we are heading into a really exciting period over the coming weeks and months with multiple milestones ahead. Very exciting for us as a company and for patients, of course, as well. CLN-978 is our T-cell engager addressing CD19, being developed for rheumatic diseases. This past summer at EULAR, we presented the first company-sponsored data for CD19 T-cell engager, and now we just announced in our corporate update this morning that we are planning to present the first multi-dose data in December. Looking forward to those data.
We also have a BCMA T-cell engager also addressing autoimmune diseases, but here we are focusing on those diseases that are driven by long-lived plasma cells. At ACR just this past week, our partners in China, Genrix Bio, presented proof of concept data in SLE, which was super exciting. Again, as I mentioned, this is a molecule where we really are focusing in on plasma cell-driven diseases, and we are starting that with our own global phase I/II study in autoimmune cytopenias. We just cleared our IND in the U.S. and Australia, so excited about that program. Our third T-cell engager is in oncology. CLN-049 is a T-cell engager addressing FLT3 in AML. This summer, we were very pleased to have a very successful end of phase I meeting with the FDA, and we have started our pivotal study in relapsed/refractory AML, actively recruiting patients into that study.
The last program I will mention, it is not a T-cell engager, it is our tyrosine kinase inhibitor addressing exon 20 non-small cell lung cancer. There, in September, we presented data from our frontline study in exon 20 non-small cell lung cancer, where we presented the best results seen to date from a median progression-free survival perspective in exon 20 disease in the frontline setting. That is a program we are partnering with Taiho, and we also announced that we have initiated our submission for that frontline indication under Real-Time Oncology Review, or RTOR. The other aspect of that program for us strategically is super important.
As part of that collaboration with our partners at Taiho, it also allows us the opportunity for near-term non-dilutive capital in the form of both regulatory milestones, where we're owed $130 million, with upcoming regulatory approvals, as well as a 50/50 profit share in the U.S., which then allows us to invest that capital back into our T-cell engager program. Hopefully that gave you an overview, a snapshot of what's happening this quarter and then into 2027.
Great. Yeah, and I think what would be helpful, let's start with CLN-978. You presented the first datasets back in June at EULAR to walk through what we saw both in SLE and RA, and then I want to walk through kind of the arc of what we should expect in December.
Sure. Yeah, happy to do that. The first thing I would say is the data we presented at EULAR earlier this summer for us really supports our belief that CLN-978 could be a breakthrough treatment for patients with autoimmune diseases. We presented single target dose data at EULAR, and there we saw clinical remissions, we saw impacts on disease-related biomarkers, and also markers of immune reset. This was above our expectations from what we would expect from single target dose data. As I mentioned, we updated the street this morning, announcing how we're going to show data in the multi-dose setting for CLN-978 coming up in December.
I think we're super excited about that opportunity there as well. As we think about all of these autoimmune diseases, what we've said is building on what we had this summer, the multi-dose data allows us the opportunity to look at initial clinical activity as well as safety and also impact on disease-related biomarkers. This really gives us an opportunity to assess clinical activity in that multi-dose setting, and then of course, we'll continue to follow patients for durability into 2027. Very exciting time for us.
Yeah, so maybe in terms of sort of from a scoping perspective, just can you talk about numbers of patients, both multi-dose for SLE and RA, and then I want to get to Sjögren's, and then what kind of follow-up we might get from some of the single-dose cohorts from earlier this year?
Yeah, sure. So, in the multi-dose setting, we announced this morning that we will have approximately 20 patients total across three different indications. We will have more lupus patients because our studies in lupus started much earlier.
We will also present data on the doses of 20 micrograms and 30 micrograms. So again, it allows us the opportunity to look at multi-dose data from a single target dose data perspective. If you remember this summer, we presented the data at EULAR. It was initial clinical activity.
Yeah. Now, for some of those responders that we saw with the single target dose data- Yeah we'll have longer follow-up, so that's exciting.
We'll also have some longer follow-up for the multi-dose patients that were accrued earlier.
Yeah. Although for the newer patients, obviously, we need longer-term follow-up.
The new piece of information really is in Sjögren's disease.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
